The short answer: nobody has studied it.
There is no trial, no label and no published protocol for moving from tirzepatide to retatrutide. Every "conversion chart" you've seen online was made up by whoever posted it. What does exist is a lot of trial data on people starting retatrutide fresh, and a growing pile of reports from people who made the switch anyway.
Here's what each of those actually says.
Status as of October 21, 2026: retatrutide is not FDA-approved. Eli Lilly plans to file in Q1 2027. Outside Lilly's trials and its expanded access program, every vial being sold is unapproved, and Lilly has sued eleven sellers and clinics since August. Nothing below is dosing advice.
Has anyone studied switching from tirzepatide to retatrutide?
No. I went through every retatrutide study registered on ClinicalTrials.gov, all 33 of them, and none is a switch study.
It goes further than that. The phase 3 trials actively keep switchers out. TRIUMPH-1, TRIUMPH-2 and the others exclude anyone who has "taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening" (ClinicalTrials.gov). So every number in the retatrutide literature comes from people who'd been off tirzepatide and everything like it for at least three months.
The closest thing coming is TRIUMPH-5, which puts retatrutide head-to-head against tirzepatide in about 800 people. That's a comparison, not a switch, and it has no results yet. Primary completion is estimated for November 2026 (NCT06662383).
What starting dose did the retatrutide trials use?
Every phase 3 trial started at 2 mg once a week and stepped up every 4 weeks (Lilly, July 23, 2026):
Target dose | Steps (4 weeks each) |
|---|---|
4 mg | 2 → 4 mg |
9 mg | 2 → 4 → 6 → 9 mg |
12 mg | 2 → 4 → 6 → 9 → 12 mg |
That 2 mg start wasn't arbitrary. Both phase 2 trials tested a 2 mg start against a 4 mg start, and both found the lower start caused fewer stomach side effects (NEJM, 2023; Lancet, 2023).
The catch for anyone switching: those people were starting from zero. Nobody in that data was coming off 15 mg of tirzepatide the week before.
For comparison, tirzepatide's own label starts at 2.5 mg for 4 weeks, goes up in 2.5 mg steps at least 4 weeks apart, and tops out at 15 mg (Zepbound label, revised 02/2026).
How long does tirzepatide stay in your system?
Tirzepatide's half-life is about 5 to 6 days (Zepbound label). Retatrutide's is about 6 days (NEJM, 2023).
The standard pharmacology rule of thumb is that a drug takes about five half-lives to mostly clear. For tirzepatide, that's roughly three and a half weeks.
So if you take your first retatrutide shot a week after your last tirzepatide shot, you have both in your body at once for a while. No trial has measured what that overlap does. One person on r/Biohacking put it plainly two days after switching: "too early to tell as still got tirz on system" (Reddit, Sept 26, 2026).
That's reasoning from half-lives, not a trial finding, and it's not a recommendation about timing. It's the thing to understand before you decide anything.
Tirzepatide vs retatrutide, side by side
Tirzepatide | Retatrutide | |
|---|---|---|
Receptors | GIP + GLP-1 | GIP + GLP-1 + glucagon |
Half-life | ~5–6 days | ~6 days |
Status | FDA-approved (Zepbound, Mounjaro) | Investigational. Filing planned Q1 2027 |
Start / max | 2.5 mg / 15 mg (label) | 2 mg / 12 mg (phase 3 trials) |
Heart rate | +1 to 3 bpm (label) | Rose early, peaked, then fell in phase 2 |
Dysesthesia (odd or painful skin sensation) | 0.2–0.4% (label) | 7.3% to 20.9% at 12 mg across phase 3 trials |
Switch data | None | None |
Different trials, different people, so read it as context, not a head-to-head. That's what TRIUMPH-5 is for.
Is retatrutide stronger than tirzepatide?
The weight loss numbers are big. In TRIUMPH-1, published in NEJM in September, average weight change at 80 weeks ranged from −17.6% to −25.0% across doses, against −3.9% on placebo (NEJM, Sept 29, 2026). Lilly's own headline for the 12 mg arm is −28.3%, which counts only people who stayed on the drug (Lilly, June 6, 2026). When you see two different numbers for the same trial, that's usually why.
But "stronger than tirzepatide" is a head-to-head claim, and the head-to-head hasn't reported. Until TRIUMPH-5 does, anyone telling you the exact difference is guessing.
One claim to drop: that retatrutide "ramps up your metabolism." The glucagon piece raised energy expenditure in mice. A 2026 paper in JCEM notes the human trials weren't designed to measure it (JCEM, 2026). It might be true in people. Nobody has shown it yet.
What do people who switched actually report?
This part is anecdote: self-reports from people using unapproved product of unknown purity and dose. It tells you what to watch for, not what will happen.
The best version of it is a study. Researchers analyzed posts from 27 subreddits and found 13,589 users reporting retatrutide use (JAMA Network Open, Oct 1, 2026). The most-reported effects were increased appetite (17.1%), fatigue (15.2%), increased energy (12.4%), nausea (11.6%) and increased heart rate (4.8%).
The switch threads from the last month line up with that:
"Do I start low even though I was maxed on tirz?" is the most common question. Most people point to the trials' 2 mg start as their reference point. Reported starting points in the threads ran from 1 mg to 2 mg (r/Retatrutide, Sept 22, 2026).
Appetite comes back during the changeover. "Tirz is a much stronger appetite suppressant" (r/Biohacking), and "the weight loss did stall while the reta is building up but it's dropping again" (r/Biohacking).
Heart rate. "I had to take a break week 5 due to HR" (r/Biohacking). One creator switched back to tirzepatide after her resting heart rate rose "by over 10 beats per minute" (YouTube).
Sleep and energy cut both ways. Some report insomnia and fatigue, others more energy than they've had in years.
Most people switching say tirzepatide stopped working. A plateau is the number one stated reason.
What to watch if you're already on it
From the trials, not the threads:
Heart rate. It rose early and then came back down in the phase 2 trials (NEJM, 2023). Track your resting heart rate from before the first shot so you have a baseline to compare against.
Skin sensation. Dysesthesia hit 20.9% at 12 mg in TRIUMPH-4, versus 0.7% on placebo. Mostly mild, rarely the reason people stopped (Lilly, Dec 11, 2025).
Blood pressure. TRIUMPH-2 saw low blood pressure in 5–6% at 9 and 12 mg versus under 1% on placebo (Lancet, Sept 29, 2026). If you're on blood pressure medication, that matters.
Stomach side effects. The most common side effect in every trial, and mostly during the step-ups.
What's actually in the vial. A BMJ Case Reports paper this month described a woman with five days of vomiting that didn't respond to three anti-nausea drugs after injections sold as retatrutide (BMJ Case Reports, Oct 7, 2026). Nobody knows what she injected. That's the point.
Where I land
I didn't switch. I went straight onto retatrutide in July, started at .5 mg, a quarter of the 2 mg the phase 3 trials started at, and worked up to 3 mg over fourteen weeks. That run is written up here, photos and all.
So I can't tell you what switching feels like. What I can tell you is what the paperwork says. The trials started everyone at 2 mg after a three-month break from weight-loss drugs. Nobody has tested what happens without that break, and tirzepatide hangs around for weeks after your last shot.
If you've made the switch, reply and tell me what you started at, how long you waited, and what you noticed. If enough of you write back, that becomes the next issue, which is more switch data than exists anywhere else right now.
For where retatrutide and every other peptide stands with the FDA, the compounding status tracker is updated when the paperwork moves. Lilly's lawsuits are broken down here.